Goldman Sachs Maintains Sell on Silence Therapeutics, Lowers Price Target to $3

Benzinga · 4d ago
Goldman Sachs analyst Richard Law maintains Silence Therapeutics (NASDAQ:SLN) with a Sell and lowers the price target from $4 to $3.